The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Open accessAbstract
Objective The metabolic side effects of second-generation antipsychotics (SGA) are serious and have not been compared head to head in a meta-analysis. We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine. Method We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE and EMBASE (last search January 2009) for randomized, blinded studies comparing the above mentioned SGA in the treatment of schizophrenia or related disorders. At least three reviewers extracted the data independently. The primary outcome was weight change. We also assessed changes of cholesterol and glucose. The results were combined in a meta-analysis. Results We included 48 studies with 105 relevant arms. Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found. Clozapine produced more weight gain than risperidone, risperidone more than amisulpride, and sertindole more than risperidone. Olanzapine produced more cholesterol increase than aripiprazole, risperidone and ziprasidone. (No differences with amisulpride, clozapine and quetiapine were found). Quetiapine produced more cholesterol increase than risperidone and ziprasidone. Olanzapine produced more increase in glucose than amisulpride, aripiprazole, quetiapine, risperidone and ziprasidone; no difference was found with clozapine. Conclusions Some SGAs lead to substantially more metabolic side effects than other SGAs. When choosing an SGA for an individual patient these side effects with their potential cause of secondary diseases must be weighed against efficacy and characteristics of the individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 1×
“…for CVD such as obesity, smoking, diabetes, hypertension and dyslipidemia are more common in patients with schizophrenia than in the general population (Fleischhacker et al., 2008), and, in addition, antipsychotic medication can induce weight gain or worsen CVD risk factors (De Hert et al., 2009).”
BackgroundBassuk, S. S., & Manson, J. E. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00160.2005 · Cited by 744
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationImportance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies
Anderson, J. W., Kendall, C. W. C., & Jenkins, D. J. A. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719316 · Cited by 448
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383
The Primary Prevention of Coronary Heart Disease in Women
Rich-Edwards, J. W., Manson, J. E., Hennekens, C. H., & Buring, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322607 · Cited by 382
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Self-citationFleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328 · cited 2×
“As a result, people with schizophrenia have a reduced life expectancy compared to the general population (Fleischhacker et al., 2008).”
BackgroundSelf-citationShared decision making in psychiatry
Hamann, J., Leucht, S., & Kissling, W. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00130.x · Cited by 306
Self-citationHennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.11.1095 · Cited by 290
Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., Rosenheck, R. A., Daumit, G. L., Hsiao, J., Swartz, M. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.487 · Cited by 286
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Self-citationZiprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 240
Self-citationDaumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223
Amisulpride versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Silveira da Mota Neto, J. I., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006624.pub2 · Cited by 205
Self-citationSertindole versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Schmid, F., Lewis, R., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006752.pub2 · Cited by 183
Self-citationKinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack-Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 165
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 158
Self-citationVancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., & Binder, M. D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.03.011 · Cited by 157
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Self-citationRisperidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., & Leucht, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006626.pub2 · Cited by 135
Self-citationArango, C., Bobes, J., Aranda, P., Carmena, R., García-García, M., & Rejas, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.009 · Cited by 109
(2004) · PubMed · Cited by 108
Aripiprazole versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., El-Sayeh, H. G. G., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub3 · Cited by 91
Self-citationZiprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials
Greenberg, W. M., & Citrome, L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00008.x · Cited by 87
Meyer, J. M., Davis, V. G., McEvoy, J. P., GOFF, D. C., Nasrallah, H. A., Thomas, S., Daumit, G. L., Hsiao, J., Swartz, M. S., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.023 · Cited by 80
Schorr, S. G., Slooff, C. J., Bruggeman, R., & Taxis, K. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.03.002 · Cited by 42
Zotepine versus other atypical antipsychotics for schizophrenia
Subramanian, S., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Kissling, W., Leucht, S., & Komossa, K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006628.pub3 · Cited by 15
Self-citationZotepine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006628.pub2 · Cited by 12
Self-citation
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citationHuhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citationHjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30078-0 · Cited by 1,304
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Metadata
- Authors
- Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 123
- Issue
- 2-3
- Pages
- 225-233
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2061525750
- Cited by
- 675
- References
- 38
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.